Using BluePrint, we will research potentially different responses of therapies to biologically different subgroups as well as our customers. In the future, we envision the medical utility of a combination of BluePrint with MammaPrint’s original 70-gene panel, said Richard Bender, MD, FACP, Chief Medical Officer of Agendia. We believe this combination offers great potential to bring the customized treatment of breasts cancer sufferers to a fresh level. .. Agendia brings new personalized treatment for breasts cancer patients Agendia, a global world innovator in molecular cancers diagnostics, today announced that its breast cancer product giving, consisting of breast cancer recurrence test MammaPrint, and TargetPrint, has been expanded with BluePrint to statement important additional information on tumor subtypes.It’s important to be mindful of what goes into the body, both food and thoughts. Learn all these details and even more at the FREE on-line Pandemic Preparedness training course at.. Academics demand more research to comprehend hospital weekend death risk Two academics from the University of Warwick state more research is needed to understand why patients will die in hospital at the weekend. Professor Richard Lilford and Dr Yen-Fu Chen of the University's Warwick Medical School, raised the issue carrying out a study that claims hospital weekend death risk is common in a number of developed countries – not only England Professor Lilford, said: Understanding this is an exceptionally important task since it is large, in regarding 10 percent in relative risk terms and 0.4 percent in %age point terms.